An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Trial Profile

An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 May 2017 Planned primary completion date changed from 1 Jun 2018 to 18 Apr 2018.
    • 23 Feb 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top